Incidence of cardiac events slightly higher with trastuzumab
the ONA take:
The cumulative incidence of cardiac events (CE) at 6 years was slightly higher in patients with HER2-positive early breast cancer receiving trastuzumab, a new study published online ahead of print in the Journal of Clinical Oncology has shown.
For the study, patients received adjuvant doxorubicin plus cyclophosphamide followed by either weekly paclitaxel (arm A), paclitaxel then trastuzumab (arm B), or paclitaxel plus trastuzumab followed by trastuzumab alone (arm C).
Results showed that the cumulative incidence of cardiac events was 0.6% in arm A, 2.8% in arm B, and 3.4% in arm C.
Researchers found that left ventricular ejection fraction (LVEF) recovered in the majority of patients that developed congestive heart failure.
The study also demonstrated that age 60 years or older, LVEF <65% at baseline, and use of antihypertensive medications were associated with an increased risk of cardiac events in patients receiving trastuzumab.
“The cumulative incidence of CE at 6 years was slightly higher with the addition of trastuzumab; however, the late development of CE is infrequent,” the authors conclude. “Trastuzumab (in the context of anthracycline- and taxane-based therapy) continues to have a favorable benefit-risk ratio.”
The cumulative incidence of cardiac events (CE) at 6 years was slightly higher in patients with HER2-positive early breast cancer receiving trastuzumab.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Radiotherapy is Essential in Treating Brain Tumors But Associated With Significant Adverse Events
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Lenvatinib Improves OS, PFS in Radioiodine-Refractory Differentiated Thyroid Cancer in All Older Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Use of Aspirin, NSAIDs Correlates with Improved Overall Survival in Colorectal Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|